Healthtech funding in H1 2024
European Healthtech startup funding raised during H1 2024.
In H1 2024, 222 European Healthtech companies closed 223 funding rounds and raised €2.2B in equity funding (excluding debt and grants), down 17.0% versus H1 2023. Debt rounds added €43M. UK led by capital raised, and The Future of Health Grant (FoHG) program was the most active investor. Data as of 20 Nov 2026.
Equity funding
€2.2B
-17.0% vs H1 2023 · excl. debt & grants · +€43M debt
Funding rounds
223
-27.8% vs H1 2023
Companies
222
Top country
UK
Rank among sectors
#7
4.6% of sector funding
Debt financing
€43M
1.9% of total
Top-10 round share
45.3%
of disclosed capital
Rounds ≥ €100M
2
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H1 2024 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €423M | 39 |
| Feb | €328M | 56 |
| Mar | €216M | 29 |
| Apr | €257M | 36 |
| May | €862M | 36 |
| Jun | €214M | 27 |
Top countries
by € raisedHealthtech — top countries by capital, H1 2024 — interactive chart.
Data table
| Healthtech — top countries by capital, H1 2024 | |
|---|---|
| UK | €942M |
| Switzerland | €367M |
| Germany | €250M |
| France | €210M |
| Finland | €122M |
| Italy | €112M |
| Netherlands | €68M |
| Sweden | €65M |
Stage mix
by € raisedHealthtech — stage mix, H1 2024 — interactive chart.
Data table
| Healthtech — stage mix, H1 2024 | |
|---|---|
| Other | €1.1B |
| Series B | €393M |
| Series C | €270M |
| Series A | €178M |
| Seed | €160M |
| Series D+ | €99M |
| Debt | €43M |
| Growth/Late | €32M |
| Grant | €18M |
| Pre-Seed | €12M |
Exits & M&A
20 Acquisition · 2 Merger22 exits · €523M disclosed.
| Calypso Biotech | Acquisition | Jan 2024 | €425M |
| Sonio | Acquisition | May 2024 | €86M |
| Apotea | Acquisition | Jan 2024 | €12M |
Top deals
largest disclosed rounds in H1 2024| Company | Stage | Date | Amount |
|---|---|---|---|
| Bicycle Therapeutics | Other | May 2024 | €512M |
| MMI | Series C | Feb 2024 | €102M |
| iOnctura | Series B | Jun 2024 | €80M |
| Timeline | Series D+ | Jan 2024 | €61M |
| Oculis | Other | Apr 2024 | €55M |
| Infinite Roots (Mushlabs) | Series B | Jan 2024 | €53M |
| Natural Cycles | Series C | May 2024 | €51M |
| Uromems | Series C | Jun 2024 | €44M |
| Grey Wolf Therapeutics | Series B | May 2024 | €42M |
| LabGenius | Other | May 2024 | €41M |
| Bob W | Series B | Feb 2024 | €40M |
| Phagenesis | Series D+ | Mar 2024 | €39M |
| Enifer | Series B | May 2024 | €36M |
| Relation Therapeutics | Seed | Mar 2024 | €32M |
| Enterprise Therapeutics | Series B | Jan 2024 | €30M |
Top investors
most active in H1 2024, by deal count- The Future of Health Grant (FoHG) program8 deals
- Innovate UK6 deals
- Elaia5 deals
- Mercia Ventures5 deals
- Bpifrance4 deals
- Octopus Ventures4 deals
- Venture Kick4 deals
- BlueYard Capital3 deals
- Eos Advisory3 deals
- Existing Shareholders3 deals